TNXP tonixpharma.com: Company Value to Revenue Ratio

Official company branding of Tonix Pharmaceuticals Holding Corp. (TNXP)

Tonix Pharmaceuticals' focus on non-opioid treatments for PTSD and fibromyalgia determines the current trajectory of the EV/Sales multiple, where the indicator reaches -2601.39. Operational stability is ensured by the protected US medical circuit, although global logistical disruptions and patent disputes create certain challenges. Broad-profile developments allow Tonix Pharmaceuticals to maneuver effectively within the humanitarian status of the industry.

TNXP tonixpharma.com: Company Value to Revenue in the range 11/23/2025 - 11/20/2026

TNXP (Tonix Pharmaceuticals Holding Corp.): analytical breakdowns and indicator data

- price and consensus price forecast:
- cash balance and cash flow data:
Fundamental company valuation:Tonix Pharmaceuticals TNXP
Product sample of tonixpharma.com

Tonix Pharmaceuticals management is coordinating the development of multiple drugs for the therapy of neurological disorders. An analysis of the enterprise value-to-revenue ratio allows for an assessment of resource allocation efficiency across various research stages. This indicator compares market capitalization and debt against sales volume, excluding the debt load. Low values may indicate undervalued assets; however, an extreme minimum signals the risk of prolonged capital stagnation.

Competitor analysis for Tonix Pharmaceuticals

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|amphastar.com (AMPH) - EV/Sales Multiple|PCRX (Pacira Pharmaceuticals) - EV/Sales Multiple|Company Value to Revenue ARS Pharmaceuticals, Inc. (SPRY)|EV/Sales Multiple TBPH|AQST (Aquestive Therapeutics) - Business Value to Revenue|scPharmaceuticals, Inc. - Company Value to Revenue|Business Value to Revenue TECX|China SXT Pharmaceuticals, Inc. - EV/Sales Multiple|EPRX - EV/Sales Multiple|BHST: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple eXoZymes Inc (EXOZ)|ORMP (oramed.com) - EV/Sales Multiple|Company Value to Revenue Ratio ENTX (Entera Bio)|Enterprise Value-to-Revenue Ratio MindWalk (HYFT)|EV/Sales Multiple ABVC BioPharma, Inc. (ABVC)|Enterprise Value-to-Revenue Ratio Cumberland Corp CPIX|QNTM - Company Value to Revenue|FGEN - Enterprise Value-to-Revenue Ratio|TELO - EV/Sales Multiple|Rani Therapeutics Inc (RANI) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio SNYR|Enterprise Value-to-Revenue Ratio Rallybio Corp|Enterprise Value-to-Revenue Ratio LEXX|EV/Sales Multiple PULM|PTHL: Enterprise Value to Sales Volume|EV/Sales Multiple APM (Aptorum Group Ltd)|LYRA - Company Value to Revenue|Impact BioMedical Inc - EV/Sales Multiple|Enterprise Value to Sales Volume TNFA|YCBD (cbdmd.com) - Company Value to Revenue|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio